System interoperability and building trust in AI capabilities are central to the strategic collaboration and organic growth plans at GE HealthCare, according to US and Canada regional president and CEO Catherine Estrampes, who spoke to In Vivo as the company released the findings of a major survey of clinicians and patients on future healthcare system needs.

The major Japanese firm says decision prompted by desire to focus more resources on late-stage clinical candidates and core therapeutic areas, while expanding deals.

Deal Snapshot: Using antibodies against an undisclosed target discovered and engineered by Innate, Takeda plans to investigate the potential of antibody-drug conjugates in celiac disease

The French drugmaker has begun an external and internal search to succeed John Reed who is heading for Johnson & Johnson after an up-and-down five years as Sanofi’s R&D chief.